Bronchiectasis is a complicating factor in more than 30 diseases, including asthma, COVID-19, chronic obstructive pulmonary disease (COPD), nontuberculous mycobacterial infections (NTM) and autoimmune diseases. It is a condition which scars the airways, making breathing increasingly difficult. The American Lung Association estimates that up to half a million people in the United States have been diagnosed with bronchiectasis — yet it often goes undiagnosed, and many more are likely to have it.

National Jewish Health has been treating bronchiectasis patients for decades, often with effective non-pharmaceutical options. More recently, our scientists have been conducting research on a promising bronchiectasis drug that is currently in phase 3 clinical trials.